Sarepta Therapeutics, Inc.

SRPT

US8036071004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
124.2 ^USD	+6.09%		+5.39%	+28.85%

Mar. 21	FDA greenlights Italfarmaco's drug for rare muscular dystrophy	RE
Mar. 12	Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM

Sarepta Therapeutics, Inc. Announces Revenue Guidance for the Year 2021

November 03, 2021 at 04:01 pm EDT

Sarepta Therapeutics, Inc. announced revenue guidance for the year 2021. Its full-year product revenue guidance by $40 million to between $605 million to $615 million.

Latest news about Sarepta Therapeutics, Inc.

FDA greenlights Italfarmaco's drug for rare muscular dystrophy	Mar. 21	RE
Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM	Mar. 12
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing	Mar. 12	MT
Transcript : Sarepta Therapeutics, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:00 AM	Mar. 11
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing	Mar. 07	MT
UBS Raises Sarepta Therapeutics Price Target to $167 From $164, Maintains Buy Rating	Mar. 01	MT
Sarepta Therapeutics' Regulatory Drug Review Underpins Prospects for Rally, RBC Says	Feb. 29	MT
Deutsche Bank Cuts Sarepta Therapeutics Price Target to $156 From $158, Maintains Buy Rating	Feb. 29	MT
Needham Cuts Price Target on Sarepta Therapeutics to $166 From $169, Maintains Buy Rating	Feb. 29	MT
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating	Feb. 29	MT
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market	Feb. 28	MT
Transcript : Sarepta Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $396.8M, vs. Street Est of $386.2M	Feb. 28	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $0.82, vs. Street Est of $0.37	Feb. 28	MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Sarepta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Prices for new US drugs rose 35% in 2023, more than the previous year	Feb. 23	RE
Sector Update: Health Care Stocks Higher Late Afternoon	Feb. 16	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 16	MT
Sector Update: Health Care	Feb. 16	MT
Sarepta Therapeutics Says FDA Grants Priority Review to Efficacy Supplement to Elevidys' BLA to Expand its Indication	Feb. 16	MT
Exchange-Traded Funds Higher, Equity Futures Mixed Ahead of Inflation Data	Feb. 16	MT
US FDA to review Sarepta's Duchenne gene therapy for traditional approval	Feb. 16	RE
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication	Feb. 16	CI
Wegovy packing supplier Catalent lays off 300 workers	Feb. 14	RE

Chart Sarepta Therapeutics, Inc.

Duration

Period

More charts

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Sarepta Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

124.2 USD

Average target price

164.5 USD

Spread / Average Target

+32.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.08%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.70%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
LEGEND BIOTECH CORPORATION	-24.93%	8.22B

Bio Therapeutic Drugs